NCT00487786 - Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

October 31, 2011

Conditions

Neoplasms

Interventions

DRUG

OGX-427

OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn

DRUG

Docetaxel

injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study

Trial Locations (3)

Seattle Cancer Care Alliance, Seattle

BC Cancer Agency, Vancouver

Juravinski Cancer Center, Hamilton